“Rising drug prices are making trips to the hospital more expensive no matter where you live,” said John Rother, executive director of the Campaign for Sustainable Rx Pricing (CSRxP). “It’s price gouging on the most vulnerable, pure and simple, and Americans are fed up.” Read More
“CAPG’s physicians experience the impact high prescription drug prices have on patients every day,” said CSRxP Executive Director John Rother. “When people cannot afford their medications because of the costly price tag, it’s harder to get and stay healthy. For CAPG physicians and their patients, prescription drug pricing is personal.” Read More
"The consequences of unaccountable price increases for EpiPens are felt every day by millions of families across the country. Sadly, this is just the latest example of drug companies trying to justify their skyrocketing price increases." Read More
Our new fact sheet illustrates how EpiPens as one example of many where drug companies institute major price hikes that compound year after year. Read More
Sustainable Drug Pricing Campaign Endorses Bipartisan Legislation… Read More
“ACHP’s expertise as a national leader in tackling health care challenges is invaluable and we are glad to have them on board," said CSRxP Executive Director John Rother. “Patient-centered community health systems work with families struggling every day to afford costly prescription drugs, and those medications are only getting more expensive.” Read More
After weeks of intense scrutiny on its pricing practices, Mylan Pharmaceuticals announced today that it would offer a coupon to patients that cannot afford life-saving EpiPens. Mylan’s public relations move does nothing address the real affordability problem facing American families: the underlying price of the medication. Read More
“Prescription drug prices rise faster than inflation every year and taxpayers are footing the bill for these higher prices. Even if you don’t take a medication, you’re paying for it," Rother noted. Read More
"The dangerous trend of high-priced drugs has to be reversed and a common-sense solution like measuring the value and cost-effectiveness of medications is one necessary step to fix the broken prescription drug market, but it must also be combined with increased transparency and competition.” Read More
It’s widely known that prescription drug prices are on the rise, but a new study attempts to undermine the role skyrocketing prescription drug prices play in increasing health care costs. The truth is that the study is critically flawed. Read More
“We are glad to see that the court rejected AstraZeneca’s effort to abuse the Orphan Drug Act and restrict generic competitors to Crestor,” said John Rother. “Additional competition in the prescription drug market—including generic options—is crucial to lowering prescription drug prices and providing patients with more affordable choices.” Read More
Members of the Campaign for Sustainable Rx Pricing (CSRxP) gathered on Capitol Hill to discuss market-based policy solutions to curb rising drug prices. Read More